Recbio's Novel Adjuvanted Shingles Vaccine Accepted for Clinical Trial in China
Jiangsu Recbio Technology Co., Ltd. is excited to announce that their research project has achieved a significant milestone. The National Medical Products Administration (NMPA) has accepted the Company's clinical trial application for their innovative adjuvanted recombinant shingles vaccine, REC610.
REC610 incorporates a novel adjuvant called BFA01, developed independently by the Company. This adjuvant effectively boosts the production of VZV glycoprotein E (gE)-specific CD4+ T cells and antibodies. The vaccine's target is to prevent shingles in adults aged 40 and above. Shingles is a viral disease that can have a severe impact on the quality of life, especially among older individuals. China sees an estimated 1.5 million new cases of shingles annually in people aged 50 and above, with a recent trend of affecting younger populations due to the fast-paced lifestyle.
Preclinical studies have demonstrated the vaccine's favorable immunogenicity, generating high levels of gE antigen-specific CD4+ T cell responses and IgG antibodies, on par with the controlled vaccine Shingrix®.
